Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day!

Area of Science:

• Infectious Diseases
• Gastroenterology
• Microbiology

Background:

• Clostridioides difficile infection (CDI) is a common healthcare-associated infection with significant recurrence rates, posing a clinical challenge.
• Current diagnostic methods like PCR may lead to false positives, necessitating refined testing strategies.
• Recurrent CDI significantly impacts patient health, with recurrence rates reaching 60% after multiple infections.

Purpose of the Study:

• To review current management and diagnostic principles for CDI.
• To summarize emerging and existing data on fecal microbiota transplantation (FMT) for CDI.
• To focus on standardized microbiota restoration therapies (SMTRs) for preventing CDI recurrence.

Main Methods:

• Review of existing literature on CDI diagnosis and treatment.
• Analysis of data from clinical trials on FMT and SMTRs.
• Comparison of recurrence prevention rates between microbiota restoration and antibiotic therapies.

Main Results:

• Microbiota restoration therapies demonstrate over 90% success in preventing CDI recurrence, significantly higher than antibiotic treatments (<50%).
• Standardized microbiota restoration therapies in capsule and enema forms show promising results in clinical trials (e.g., SER-109, RBX2660).
• Fecal microbiota transplantation, while effective, faces challenges with heterogeneity and adverse events, driving the development of standardized alternatives.

Conclusions:

• Standardized microbiota restoration therapies represent a highly effective strategy for managing recurrent CDI.
• Emerging standardized therapies offer improved safety and efficacy profiles compared to traditional FMT.
• Refined diagnostic approaches and advanced microbiota restoration therapies are crucial for addressing the CDI challenge.